April 7, 2010 – Pulmonary-Allergy Drugs Advisory Committee
NDA – roflumilast/DAXAS (Forest Research)
Agenda: On April 7, 2010, the committee will discuss new drug application (NDA) 22-522, roflumilast (DAXAS), Forest Research Institute, for the maintenance treatment of chronic obstructive pulmonary disease associated with chronic bronchitis in patients at risk of exacerbations (worsening symptoms).
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment